SynthesisMedicine2016
Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: A preliminary meta-analysis under MOOSE guidelines.
Synthesis in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders.Translational psychiatry · 2020Pooled it
- Environmental enrichment and physical exercise prevent stress-induced social avoidance and blood-brain barrier alterations via Fgf2.Nature communications · 2026Article
- Paeoniflorin and depression: a comprehensive review of underlying molecular mechanisms.Metabolic brain disease · 2025Review
- Emergence of Extracellular Vesicles as "Liquid Biopsy" for Neurological Disorders: Boom or Bust.Pharmacological reviews · 2024Review
- The roles of extracellular vesicles in major depressive disorder.Frontiers in psychiatry · 2023Review
- Chronic Trazodone and Citalopram Treatments Increase Trophic Factor and Circadian Rhythm Gene Expression in Rat Brain Regions Relevant for Antidepressant Efficacy.International journal of molecular sciences · 2022Article
- Article
- Article
- In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Update on the Relationship Between Depression and Neuroendocrine Metabolism.Frontiers in neuroscience · 2021Review
- Peripheral Markers of Depression.Journal of clinical medicine · 2020Review
- Fibroblast Growth Factors in Depression.Frontiers in pharmacology · 2019Review
- Alterations in the Levels of Growth Factors in Adolescents with Major Depressive Disorder: A Longitudinal Study during the Treatment with Fluoxetine.Mediators of inflammation · 2019Article
- Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- MicroRNA-27a participates in the pathological process of depression in rats by regulating VEGFA.Experimental and therapeutic medicine · 2018Article
- Nitrite-induced acute kidney injury with secondary hyperparathyroidism: Case report and literature review.Medicine · 2018Review
- Biomarkers for depression: recent insights, current challenges and future prospects.Neuropsychiatric disease and treatment · 2017Review
- The Association Between Salivary FGF2 and Physiological and Psychological Components of the Human Stress Response.Chronic stress (Thousand Oaks, Calif.)Article
- A narrative review on invasive brain stimulation for treatment-resistant depression.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn vivo and in vitro studies demonstrate the important roles of fibroblast growth factor (FGF) and FGF receptors (FGFRs) in neural survival, neurogenesis, oxidative stress, and emotional behavior. However, evidence on the role of FGF and FGFR in the pathophysiology of major depressive disorder (MDD) remains limited and inconclusive.
objectivesThis preliminary meta-analysis aimed to examine changes in peripheral or central FGF and FGFR levels in patients with MDD. DATA SOURCES: Electronic research through platform of PubMed and ClinicalTrials.gov. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND
interventionsWe used the inclusion criteria: articles discussing the comparisons of FGF levels, either in peripheral or central environment, in patients with MDD and in healthy controls (HC); articles on clinical trials in humans; and case-control trials. Case reports or series and nonclinical trials were excluded. STUDY APPRAISAL AND SYNTHESIS
methodsUsing a thorough literature search, the FGF/FGFR levels in patients with MDD and HC were compared. Four studies on peripheral FGF-2 and 3 on central FGF-2 and FGFR1 levels were included.
resultsThe findings reveal significantly higher peripheral FGF-2 protein and central FGFR1 RNA levels in patients with MDD than in HC (P = 0.005 and 0.006, separately), but no significant association with clinical variables. There was also no significant difference in the central FGF-2 levels in patients with MDD and in HC (P = 0.180). LIMITATION: The study has limitations of a small number of included studies, lack of meta-analysis of the FGF changes along with treatment, and lack of direct evidence on correlation of peripheral FGF-2 with central FGF-2 levels. CONCLUSIONS AND IMPLICATIONS OF KEY
findingsThis preliminary meta-analysis points out a new direction for future studies investigating the relationship among MDD, oxidative stress, and the FGF family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.